| Accession |
PRJCA019008 |
| Title |
Phosphoproteomic Characterization and Kinase Signature Predict AML Patients Response to Venetoclax plus 3+7 Daunorubicin and Cytarabine Chemotherapy |
| Relevance |
Medical |
| Data types |
proteome
|
| Organisms |
Homo sapiens
|
| Description |
Chemotherapy resistance remains a formidable obstacle in the therapeutic management of acute myeloid leukemia, necessitating the exploration of optimal strategies to augment therapeutic benefit.In a recent phase trial, we evaluated the DA plus V chemotherapy In a recent phase trial, we evaluated the DA plus V chemotherapy regimen in adult AML patients.To elucidate the underlying mechanistic determinants governing the response to DAV in AML, we adopted an exhaustive quantitative phosphoproteomics to discern distinct molecular signatures characterizing the subset of DAV-sensitive patients. |
| Sample scope |
Multiisolate |
| Release date |
2023-08-12 |
| Publication |
| PubMed ID |
Article title |
Journal name |
DOI |
Year |
| 38161214
|
Phosphoproteomic Characterization and Kinase Signature Predict Response to Venetoclax Plus 3+7 Chemotherapy in Acute Myeloid Leukemia
|
Advanced Science
|
10.1002/advs.202305885
|
2023
|
|
|
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Fundamental Research Funds for the Central Universities
|
|
226-2022-00003
|
|
|
|
| Submitter |
Yinghui
Zhu (zhuyinghui1989@hotmail.com)
|
| Organization |
Tongji University |
| Submission date |
2023-08-12 |
